Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir

PURPOSE: Dolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects. METHODS: The first study was an open-label crossover where 12 s...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ivy, Borland, Julie, Chen, Shuguang, Guta, Phyllis, Lou, Yu, Wilfret, David, Wajima, Toshihiro, Savina, Paul, Peppercorn, Amanda, Castellino, Stephen, Wagner, David, Hosking, Louise, Mosteller, Michael, Rubio, Justin P., Piscitelli, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158172/
https://www.ncbi.nlm.nih.gov/pubmed/25146692
http://dx.doi.org/10.1007/s00228-014-1732-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158172/
https://www.ncbi.nlm.nih.gov/pubmed/25146692
http://dx.doi.org/10.1007/s00228-014-1732-8

Ejemplares similares